Skip to main content
OpenTrials
Completed

NCT Number: NCT03329963

Lifestyle Intervention to Improve Bone Quality

Obese older adults will be randomized to participate in either healthy lifestyle intervention or behavioral diet and exercise intervention for one year. This study aims to determine the effects of Lifestyle intervention on bone microarchitecture, bone strength, bone material properties, and the mechanism behind it.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Michael E Debakey VA Medical Center

Houston, Texas, 77030, United States

About this study

Previous studies had suggested that lifestyle therapy (diet plus exercise) resulting in weight loss in elderly population improves physical function, cardio metabolic risk factors, and cognition/quality of life, but a major complication is loss of BMD. The addition of exercise to diet-induced weight loss attenuated but did not eliminate weight-loss-induced reduction of BMD. Moreover, while long-term maintenance of weight loss and physical function was feasible, sustained lifestyle change led to continued loss of hip BMD, which might predict hip fractures. Although similar BMD loss with weight loss has been observed in younger populations, BMD loss in older adults might be of particular concern because of aggravation of age-related bone loss. Moreover, the belief that obesity protects against fractures has now been challenged by studies demonstrating that obesity is associated with poor bone quality and ankle and leg fractures.Because of previous lack of options to assess bone quality in vivo, there has been little or no scientific study of the possibility that lifestyle therapy in obese older adults improves bone quality. This study represents an unprecedented opportunity to prove the hypothesis that lifestyle therapy intervention improves bone quality and thus, may confer a protective rather than adverse effect on bone health. This will be the first randomized controlled trial (RCT) to comprehensively assess bone quality using novel techniques in response to lifestyle therapy in obese older adults, with major ramifications with regards to defining optimal treatment strategies for this increasingly high-risk older population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 65 - 85 years • BMI 30 kg/m2 or more• Stable body weight (±2 kg) during the past 6 months • Sedentary (regular exercise <1 h/wk. or <2 x/wk. for the last 6 months) • Willing to provide informed consent

Exclusion criteria

  • Failure to provide informed consent.
  • Any major chronic diseases, or any condition that would interfere with exercise or dietary restriction, in which exercise or dietary restrictions are contraindicated, or that would interfere with interpretation of results
  • Cardiopulmonary disease (e.g. recent myocardial infarction, unstable angina, stroke) or unstable disease (e.g., New York Heart Class III or IV congestive heart failure, severe pulmonary disease requiring steroid pills or the use of supplemental oxygen ) that would contraindicate exercise or dietary restriction
  • Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, amyotrophic lateral sclerosis, active rheumatoid arthritis) disease or impairments that would contraindicate participation in exercise
  • Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention (e.g. renal failure on hemodialysis, severe psychiatric disorder [e.g. bipolar, schizophrenia], excess alcohol use [more than14 drinks per week])
  • Severe visual or hearing impairments that would interfere with following directions
  • Significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State Exam score less than 24)
  • Uncontrolled hypertension (BP>160/90 mm Hg)
  • History of malignancy during the past 5 years (except non-melanoma skin cancers)
  • Current use of bone acting drugs (e.g. use of estrogen, or androgen containing compound, raloxifene, calcitonin, parathyroid hormone during the past year or bisphosphonates during the last two years)
  • Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragility fractures - Diabetes mellitus requiring insulin for treatment or with a fasting blood glucose of >140 mg/dl, and/or HbA1c >8.5% (Those excluded from the study because of fasting blood glucose of >140 mg/dl or HbA1c>8.5% will be referred to their primary care provider for follow-up and appropriate treatment).
  • Terminal illness with life expectancy less than 12 months, as determined by a physician
  • Use of any drugs or natural products designed to induce weight loss within past three months.
  • Positive exercise stress test for ischemia

Treatment and study plan

Healthy lifestyle intervention

Behavioral

Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.

Lifestyle Intervention

Behavioral

The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last ~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent "treatment fatigue". A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.

The exercise sessions are of ~90 min duration (~15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing.

Primary outcomes

  1. Change in cortical thickness

    Time frame: Change from baseline at 12 months

    Assessed by using high-resolution peripheral computed tomography (HR-pQCT)

  2. Change in femoral bone strength

    Time frame: Change from baseline at 12 months

    Assessed by using finite element analyses (FEA) of quantitative computed tomography (QCT)

Secondary outcomes

  1. Change in bone material strength

    Time frame: Change from baseline at 12 months

    Assessed by using microindentation testing

  2. Change in lower extremity strength

    Time frame: Change from baseline at 12 months

    Assessed by using a Biodex dynamometer

  3. Change in physical performance test

    Time frame: Change from baseline at 12 months

    assessed by using the objective physical performance test

  4. Change in gait speed

    Time frame: Change from baseline at 12 months

    as measured by completing the time to walk a certain distance

  5. Change in handgrip strength

    Time frame: Change from baseline at 12 months

    Measured by hydraulic hand dynamometer

  6. Change in trabecular thickness

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  7. Change in areal bone mineral density (BMD)

    Time frame: Change from baseline at 12 months

    Assessed by using dual-energy x-ray absorptiometry

  8. Change in trabecular number

    Time frame: Change from baseline at 12 month

    Assessed by using HR-pQCT

  9. Change in total volumetric BMD

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  10. Change in cortical volumetric BMD

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  11. Change in trabecular volumetric BMD

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  12. Change in stiffness

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  13. Change in trabecular separation

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  14. Change in micro-finite element analyses strength

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  15. Change in cortical porosity

    Time frame: Change from baseline at 12 months

    Assessed by using HR-pQCT

  16. Change in general quality of life

    Time frame: Change from baseline at 12 months

    Assessed by using the Short Form-36 questionnaire

  17. Change in obesity specific quality of life

    Time frame: Change from baseline at 12 months

    Assessed by using the Impact of weight on quality of life short form (IWQOL-Lite) questionnaire

  18. Change in mood

    Time frame: Change from baseline at 12 months

    Assessed by using a mood scale questionnaire

  19. Change in composite cognitive z-score

    Time frame: Change from baseline at 12 months

    Using cognitive instrument testing

  20. Change in cardio metabolic risk factors

    Time frame: Change from baseline at 12 months

    Assessed by measuring metabolic syndrome components

  21. Change in word list fluency

    Time frame: Change from baseline at 12 months

    Assessed by using cognitive instrument testing

  22. Change in Ray Auditory verbal learning test

    Time frame: Change from baseline at 12 months

    Assessed by using cognitive instrument testing

  23. Change in blood pressure

    Time frame: Change from baseline at 12 months

    Assessed by usingSphygmomanometer

  24. Change in biochemical marker for bone turnover and bone metabolism

    Time frame: Change from baseline at 12 months

    Assessed by using enzyme linked immunosorbent assay and radioimmunoassay

  25. Change in central volumetric BMD

    Time frame: Change from baseline at 12 months

    Assessed by using CT scan at the spine and hip

  26. Change in waist circumference

    Time frame: Change from baseline at 12 months

    Assessed by using tape measurement

  27. Change in lean mass

    Time frame: Change from baseline at 12 months

    Assessed by using dual-energy x-ray absorptiometry

  28. Change in fat mass

    Time frame: Change from baseline at 12 months

    Assessed by using dual-energy x-ray absorptiometry

  29. Change in visceral fat

    Time frame: Change from baseline at 12 months

    Assessed by using dual-energy x-ray absorptiometry

  30. Change in physical activity using accelerometer

    Time frame: Change from baseline at 12 months

    Assessed by using an accelerometer

  31. Change in body weight

    Time frame: Change from baseline at 12 months

    Assessed by using weighing scale

  32. Change in sclerostin

    Time frame: Change from baseline at 12 months

    Assessed by using enzyme linked immunoassay

  33. Change in wnt signaling pathways

    Time frame: Change from baseline at 12 months

    Assessed by measurements of circulating levels of Wnt 5a and Sfrp5

  34. Change in total body mass

    Time frame: Change from baseline at 12 months

    Assessed byusing dual energy x-ray absorptiometry

  35. Change in hormones

    Time frame: Change from baseline at 12 months

    Assessed by usingenzyme link immunoassay

  36. Change in thigh mass

    Time frame: Change from baseline at 12 months

    Assessed by using CT scan

  37. Change in circulating cytokines

    Time frame: Change from baseline at 12 months

    Assessed by using enzyme linked immunoassay

  38. Change in adipocytokines

    Time frame: Change from baseline at 12 months

    Assessed by using enzyme linked immunoassay

  39. Change in total volumetric BMD

    Time frame: Change from baseline at 12 months

    Assessed by using QCT Pro software

  40. Change in cortical trabecular BMD

    Time frame: Change from baseline at 12 months

    Assessed by using QCT Pro software

  41. Change in aerobic capacity

    Time frame: Change from baseline at 12 months

    Assessed by using indirect calorimetry during graded treadmill test

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Biomedical Research Institute of New Mexico
  • Michael E. DeBakey VA Medical Center
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Does Lifestyle Intervention Improve Bone Quality in Obese Older Adults?

Acronym: LIMB-Q

Important dates

Study start
2017
Primary completion
2023
Study completion
2023
First posted
Nov 6, 2017
Registry last updated
Jun 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.